巨子 ICON - 財經股票資訊及專家分析
快訊
資訊
    虛擬市場
    搜尋 股票/指數/編號

    快訊

    資訊

    Checkpoint Therapeutics

    CKPT
    1.060
    0.040
    3.64%
    最少15分鐘延遲,股票資訊由第三方資訊供應商提供
    ・Checkpoint Therapeutics - 延遲價格・最後更新於 29/06 12:14
    最高位
    1.100
    最低位
    1.060
    開市價
    --
    前收市價
    1.100
    成交量(千)
    2.56
    成交額(百萬)
    0.03
    買入
    --
    賣出
    --
    每手股數
    --
    市值(百萬)
    96.49
    市盈率
    --
    息率
    --
    差價
    --
    52週高低
    4.640 - 0.960
    所有資料不保證絕對正確、完整、或實時,僅作為參考使用。投資涉及風險,過往業績並不代表將來表現,作任何投資決定或交易前,閣下應諮詢獨立專業意見。所有內容均不構成投資建議。

    企業資料

    公司名稱
    Checkpoint Therapeutics
    證券代碼
    CKPT.US
    所屬板塊
    Biotechnology
    公司業務
    Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
    發行量
    91026442
    公司總部
    95 Sawyer Road, Suite 110
    公司網址
    https://www.checkpointtx.com
    公司電郵
    ir@checkpointtx.com
    公司電話
    +1 781 652-4500
    暫無內容

    關於

    Checkpoint Therapeutics(CKPT.US)所屬的行業板塊為Biotechnology。
    Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
    詳細公司背景可參考: https://www.checkpointtx.com